Semaglutide Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217 For research use only

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).

Products Details

Semaglutide, sold under the brand names OzempicWegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and as anti-obesity medication for long-term weight management, developed by Novo Nordisk in 2012. Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control. Side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation. In December 2017, the injectable version named Ozempic was approved. In September 2019, a version which can be taken by mouth (Rybelsus) was approved, and in June 2021, a higher-dose injection sold under the brand name Wegovy for long-term weight management in adults was approved by the US Food and Drug Administration (FDA). In January of 2023, FDA gave Novo Nordisk permission to revise the label to indicate that oral Rybelsus can be used as a first-line treatment for adults with type 2 diabetes—meaning in people who have not previously taken another diabetes medication. In 2020, semaglutide was the 129th most commonly prescribed medication in the United States, with more than 4 million prescriptions. Synonyms: Rybelsus, Ozempic, NN9535, OG217SC, For research use only.

Semaglutide Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217 For research use only (3)

Biological Activity

Description Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Targets GLP-1 receptor
In vitro Semaglutide is selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) is three-fold decreased compared to liraglutide, whereas the albumin affinity is increased.
In vivo The plasma half-life is 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.

Protocol (from reference)

Cell Research: ● Cell lines: BHK cells ● Concentrations: 0.01 pM - 0.1 μM ● Incubation Time: 3 h ● Method: Frozen aliquots of BHK cells that express both the hGLP-1R and CRE firefly luciferase (clone FCW467-12A/KZ10-1) are thawed, washed twice in PBS, and suspended in assay buffer. Cells are plated out into 96-well plates at 5000 cells/well in a volume of 50 μL. Compounds to be tested are diluted in assay buffer and a 50 μL aliquot transferred to the plate containing the cells to reach final assay concentrations of 1 × 1014 − 1 × 107 M. The plate is incubated for 3 h at 5% CO2 at 37 °C. The plate was allowed to stand at room temperature for 15 min prior to adding 100 μL of steadylite plus reagent. The plate is covered to protect it from light and shaken at room temperature for 30 min. The plate is read in a TopCount NXT instrument.
Solubility (25°C)
In vitroBatch:    DMSO 3 mg/mL(0.73 mM)
Ethanol Insoluble
Water Insoluble
Chemical Information

Molecular Weight 4113.58
Formula C187H291N45O59
CAS No. 910463-68-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Shipping Room temperature shipping(Quality concern free: the product is good at 37℃ for at least 1 week.)
Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05537233 Not yet recruiting Drug: Semaglutide|Drug: Placebo Type 1 Diabetes|Obesity University of Colorado Denver|Juvenile Diabetes Research Foundation January 1 2023 Phase 2
NCT04885634 Not yet recruiting Drug: Semaglutide Injectable Product|Drug: Placebo Atrial Fibrillation|Overweight and Obesity Axel Brandes|Herlev and Gentofte Hospital|Hillerod Hospital Denmark|Svendborg Hospital|Hospital of South West Jutland|Odense University Hospital October 2022 Phase 3
NCT05579977 Recruiting Drug: PF-07081532|Other: Placebo|Drug: Rybelsus Diabetes Mellitus|Obesity Pfizer October 27 2022 Phase 2
NCT05254314 Recruiting Drug: Semaglutide Pen Injector 2.4mg weekly|Other: Placebo Asthma Vanderbilt University Medical Center|National Institute of Allergy and Infectious Diseases (NIAID) September 7 2022 Phase 2
NCT05478252 Recruiting Drug: Semaglutide J|Drug: Semaglutide B Diabetes Mellitus Type 2 Novo Nordisk A/S August 3 2022 Phase 3
(data from https://clinicaltrials.gov, updated on 2022-11-29)

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours